Lataa...
Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
BACKGROUND: The availability of a dual sodium glucose co‐transporter 2/dipeptidyl peptidase‐4 inhibitor combination in a single‐tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and...
Tallennettuna:
| Julkaisussa: | Int J Clin Pract |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5049636/ https://ncbi.nlm.nih.gov/pubmed/26303997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12720 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|